Scientists at the University of California San Francisco (UCSF) have designed a group of synthetic molecules that could prevent the rejection of allogeneic cell transplants. Their strategy consisted of activating the immune checkpoints of different populations of immune cells from the cell surface, but avoiding the cytotoxicity of natural killer (NK) cells and macrophages that would destroy the transplanted cells.
The National Institute of Allergy and Infectious Diseases (NIAID) is set to conduct a phase I trial with Tonix Pharmaceuticals Holding Corp.’s TNX-1800 (recombinant horsepox virus, live vaccine), a vaccine candidate to protect against COVID-19.
The Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford have launched a new project to initiate early development of prototype vaccines against the Junín virus, selected as an exemplar of the Arenavirus family which is responsible for multiple deadly hemorrhagic fevers with epidemic and pandemic potential.
Viridian Therapeutics Inc. has disclosed a preclinical portfolio of neonatal Fc receptor (FcRn) inhibitors designed for next-generation treatment of antibody-mediated autoimmune diseases.
VBI Vaccines Inc. has announced the development of its next-generation mRNA-launched enveloped virus-like particle (eVLP) technology, which expands on the company's current proprietary eVLP technology by coding the particles in messenger RNA (mRNA).
Triveni Bio Inc. has announced a $92 million series A financing that will support the advancement of its lead antibody program, TRIV-509, from preclinical development to a phase IIa clinical trial in atopic dermatitis and fuel a pipeline of novel antibodies with two additional development candidate nominations expected in 2024.
Korean bioventure GI Innovation Inc. inched closer to achieving its goal of “five tech transfer deals in five years” with another licensing deal for its allergy drug, GI-301, with Japan-based Maruho Co. Ltd. for ₩298 billion (US$220.7 million), although share prices still dropped on the news.
A new deal between privately held Hummingbird Bioscience Pte. Ltd. and Endeavor Biomedicines Inc. is just one of three antibody-drug conjugate (ADC) agreements reached in the past week, marking a fourth-quarter surge for the therapy.
Vaxcyte Inc. has received FDA clearance of its IND application for VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate designed to prevent invasive pneumococcal disease.
Activated phosphoinositide 3-kinase δ syndrome type 1 (APDS1) is a rare disease caused by gain-of-function (GOF) mutations in the PIK3CD gene that presents with combined immunodeficiency due to decreases in IgA, IgG, naive CD4 and naive CD8 cells. Nearly all APDS1 patients suffer from recurrent respiratory tract infections with most presenting with bronchiectasis and chronic viral infections.
RSS
